News

Researchers at Georgetown University Medical Center (GUMC) are recruiting participants for a clinical trial to evaluate the cancer drug Tasigna (nilotinib) in people with mild to moderate Alzheimer’s disease (AD). The randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT02947893) will evaluate how low doses of Tasigna impact safety, biomarkers, and…

Meditating or listening to music may benefit adults with preclinical memory loss, including those at risk for Alzheimer’s disease (AD), a new study found. A West Virginia University research team, led by Kim Innes, PhD, conducted a randomized, controlled clinical trial in 60 adults with subjective cognitive decline (SCD),…

Cognitive decline can be triggered by the ApoE4 gene variant, but that trigger depends on environmental factors, a new study reports. This finding supports the idea that certain diseases, such as Alzheimer’s, are influenced by the interaction between a person’s genes and environment. The study, “Apolipoprotein E4 Is Associated…

Selonterra researchers have discovered that the APOE4 gene impacts Alzheimer’s disease (AD) mechanisms in an entirely different way than previously believed. The mutation does not change the behavior of the protein itself, but triggers the activation of nearby genes, which may contribute to Alzheimer’s. The study,…

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Harrington Discovery Institute are calling for proposals for their 2017 ADDF-Harrington Scholar Award, which supports innovative research that aims to prevent, treat or cure Alzheimer’s disease (AD). Applicants are eligible to receive financial support over two years of up…

Molecules blocking a receptor found in the brain called 5-HT6R could potentially be used to treat Alzheimer’s disease, according to two studies led by researchers at Moscow Institute of Physics and Technology (MIPT), according to a news release. The first study “AVN-211, Novel and Highly Selective 5-HT6 Receptor Small…

A group of patients with inherited forms of Alzheimer’s disease was found to have extremely high brain-aluminum levels, leading researchers to suggest there might be a link between genetic vulnerability to the condition and a higher susceptibility to accumulate aluminum in the brain. “Aluminium in brain tissue in familial…

As the disappointment over the failure of solanezumab begins to wane, George Vradenburg, co-founder and chairman of UsAgainstAlzheimer’s, seeks to address the efforts needed to continue research and clinical development for Alzheimer’s disease. Despite the inability of Eli Lilly to bring the goods to the table, Vradenburg applauded Lilly’s…

Honor is collaborating with the Alzheimer’s Association to educate its Care Pros on how to better care for people living with Alzheimer’s disease. Start-up company Honor offers tech-powered home care for older adults. The new agreement follows similar collaborations, such as the National Parkinson Foundation and the American Cancer Society.

Genervon Biopharmaceuticals recently shared a previously confidential list of 84 genes linked to Alzheimer’s disease which are modulated by their investigational treatment GM6. The move to make the list public was based on a wish to encourage more neurological scientists to investigate broader, multi-target approaches to treat diseases…